Doctors' perceptions of psoriasis therapies vary

February 7, 2013
Doctors' perceptions of psoriasis therapies vary
Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

Katrina Abuabara, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues surveyed 246 members of the National Psoriasis Foundation and 141 members of the American Academy of Dermatology about the safety and effectiveness of psoriasis treatments.

The researchers found that , ustekinumab, cyclosporine, and adalimumab were regarded as being most likely to clear skin in three months (67 to 75 percent). Etanercept, , ultraviolet B, and ustekinumab were regarded as being the least likely to produce side effects requiring discontinuation of treatment (9 to 11 percent). In both cases, up to 49 percent "didn't know" the effectiveness or the likelihood of side effects, and the coefficients of variation were higher for the perceived likelihood of side effects. There were few significant correlations between perceptions and respondent characteristics, and perceptions could not be consistently predicted by treatment preference.

"Psoriasis providers demonstrate wide variation in their perception of the effectiveness and especially safety of systemic treatments," Abuabara and colleagues conclude.

Several authors disclosed to the pharmaceutical industry.

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Many psoriasis patients undertreated for CV risk factors

June 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal ...

Short/long-term analyses deem etanercept safe for psoriasis

July 29, 2012

(HealthDay) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal ...

Reasons for discontinuation vary by psoriasis treatment

August 10, 2012

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Recommended for you

Cellphone data can track infectious diseases

August 20, 2015

Tracking mobile phone data is often associated with privacy issues, but these vast datasets could be the key to understanding how infectious diseases are spread seasonally, according to a study published in the Proceedings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.